Quince Therapeutics Inc (QNCX) Stock Price, Quote & News

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 910 5717

Website: www.quincetx.com

Address:

611 Gateway Boulevard, Suite 273, South San Francisco, United States

H96 Mar. 21 at 7:13 PM

$QNCX please announce something good next week I am drown in debts and my wedding in August. This is my last hope guys after that man down😭😭🙏🙏🙏

5 · Reply

Jayray9999 Mar. 21 at 6:11 PM

$QNCX last time it had this much ownership was 2021 where they had SLIGHTLY more . This is going to be interesting to say the very least .

0 · Reply

Papluch Mar. 21 at 4:01 PM

$QNCX The Nasdaq notice doesn’t have a disruptive influence in the process, It actually accelerates the need to finish the merger. This now pushes them to close sooner rather than later, Mergers generally are announced after earnings, When is the earnings again 😂🤔🚀

1 · Reply

sullivan1 Mar. 21 at 3:51 PM

$QNCX close above 10c on .Monday will pump this above 30c next week

0 · Reply

StocksRocks333 Mar. 21 at 3:38 PM

$QNCX Do you think its possible for this to go up?

0 · Reply

sullivan1 Mar. 21 at 2:43 PM

$QNCX Me too. Feared of missing out and added more 😁

1 · Reply

lorenaw Mar. 21 at 2:31 PM

$QNCX I’m scared here 😨😨 lol clock is ticking here ⏰⏰⏰.. I run out of snacks 🤣😂needs💰💰💰

0 · Reply

sullivan1 Mar. 21 at 2:29 PM

$QNCX The Company intends to actively monitor the closing bid price for its common stock and will consider available options to resolve the deficiency and regain compliance with Nasdaq Listing Rule 5450(a)(1

0 · Reply

sullivan1 Mar. 21 at 2:27 PM

$QNCX https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319891408&type=PDF&symbol=QNCX&cdn=d57721bcd92e2f85f3ae7f1a845e38e2&companyName=Quince+Therapeutics+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2026-03-20

0 · Reply

Alswndwl Mar. 21 at 1:44 PM

$QNCX When is the 10-K filing expected?

0 · Reply

Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks

Feb 10, 2026, 3:05 PM EST - 5 weeks ago

Quince Therapeutics Stock Explodes 300% On Strategic Review

Feb 9, 2026, 4:05 PM EST - 5 weeks ago

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Jan 29, 2026, 3:10 PM EST - 7 weeks ago

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Jan 28, 2026, 4:05 PM EST - 7 weeks ago

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Dec 15, 2025, 8:00 AM EST - 3 months ago

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Dec 10, 2025, 4:05 PM EST - 3 months ago

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Nov 24, 2025, 8:00 AM EST - 4 months ago

Quince Therapeutics to Participate at Investor Events in December 2025

Nov 12, 2025, 4:05 PM EST - 4 months ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 4:05 PM EST - 4 months ago

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Oct 9, 2025, 4:05 PM EDT - 5 months ago

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Sep 25, 2025, 4:05 PM EDT - 6 months ago

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Sep 11, 2025, 4:05 PM EDT - 6 months ago

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Sep 2, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 8 months ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Jul 16, 2025, 8:00 AM EDT - 8 months ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 10, 2025, 4:05 PM EDT - 9 months ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jun 25, 2025, 4:05 PM EDT - 9 months ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 18, 2025, 4:05 PM EDT - 9 months ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 10 months ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 3, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

May 13, 2025, 8:00 AM EDT - 11 months ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 3, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Feb 7, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 5, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 23, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Nov 13, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 11, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

May 13, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 2 years ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Feb 22, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Launches Scientific Advisory Board

Feb 15, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Feb 7, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 4, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Participate at Investor Events in January 2024

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Sep 28, 2023, 4:05 PM EDT - 2 years ago

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

H96 Mar. 21 at 7:13 PM

$QNCX please announce something good next week I am drown in debts and my wedding in August. This is my last hope guys after that man down😭😭🙏🙏🙏

5 · Reply

Jayray9999 Mar. 21 at 6:11 PM

$QNCX last time it had this much ownership was 2021 where they had SLIGHTLY more . This is going to be interesting to say the very least .

0 · Reply

Papluch Mar. 21 at 4:01 PM

1 · Reply

sullivan1 Mar. 21 at 3:51 PM

$QNCX close above 10c on .Monday will pump this above 30c next week

0 · Reply

StocksRocks333 Mar. 21 at 3:38 PM

$QNCX Do you think its possible for this to go up?

0 · Reply

sullivan1 Mar. 21 at 2:43 PM

$QNCX Me too. Feared of missing out and added more 😁

1 · Reply

lorenaw Mar. 21 at 2:31 PM

$QNCX I’m scared here 😨😨 lol clock is ticking here ⏰⏰⏰.. I run out of snacks 🤣😂needs💰💰💰

0 · Reply

sullivan1 Mar. 21 at 2:29 PM

0 · Reply

sullivan1 Mar. 21 at 2:27 PM

0 · Reply

Alswndwl Mar. 21 at 1:44 PM

$QNCX When is the 10-K filing expected?

0 · Reply

victory369 Mar. 21 at 10:57 AM

$QNCX Sound.very scary man

0 · Reply

makesomemoneybro123 Mar. 21 at 8:36 AM

$QNCX are you one of them? We all knew about delisting problem, the thing here is trying to get the share price over 0.10

1 · Reply

majsterJoda Mar. 21 at 7:46 AM

$QNCX shorts gonna get this to 5c or lower before delist run

1 · Reply

sullivan1 Mar. 21 at 4:51 AM

$QNCX The whole manipulation is about Lighthouse 7.5% stake abd $150M Royalty

0 · Reply

sullivan1 Mar. 21 at 4:49 AM

$QNCX Under strong manipulation. This may act like $AND run upto 50-60c before getting delisted imo

0 · Reply

AlienTrador Mar. 21 at 4:43 AM

$QNCX its gonna hit one cent

0 · Reply

victory369 Mar. 21 at 3:57 AM

$QNCX Exactly

0 · Reply

sullivan1 Mar. 21 at 3:06 AM

$QNCX They have just 5 days to go above 10c else delisted

1 · Reply

victory369 Mar. 21 at 1:06 AM

$QNCX Yeah but they better keep it 0.10 + Not under 0.10 cents 😁

1 · Reply

BULLETSTOCK Mar. 21 at 12:42 AM

$QNCX they have until September 14, 2026—about 6 months from now—to fix both issues . relax $$$$

1 · Reply

soulsearche Mar. 20 at 11:46 PM

$QNCX we knew it all the time. we were not at their mercy. DYOR

1 · Reply

ZeebraNotZebra Mar. 20 at 11:00 PM

$QNCX they knew they faced listing compliance since the beginning of the week and didn't even care to tell us. I'm out from this mess.

0 · Reply

Market Cap	5.40M
Revenue (ttm)	0.00
Net Income (ttm)	-56.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	16.53

Volume	14,002,600
Avg Vol	79,263,414
Day's Range	N/A - N/A
Shares Out	55.68M
Stochastic %K	0%
Beta	1.28
Analysts	Hold
Price Target	$6.50